menu
    • menu

    Company profile for Zhejiang Hisun Chemical Co., Ltd.

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Fishfa Biogenics: Renowned Manufacturer, & Exporter of Tacrolimus & Mupirocin API.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Zhejiang Hisun Chemical Co., Ltd (hereafter called as ”Hisun Chemical), founded in 1998, is a state-holding enterprise invested by State Development & Investment Corporation(SDIC), Zhejiang Hisun Group and ZMC Co., Ltd. The company now covers an area of 312,000 square meters and 35% of its staff members are technicians. With its total assets of nearly USD 60 million, Hisun Chemical has created a niche in agrochemical field t...
    Zhejiang Hisun Chemical Co., Ltd (hereafter called as ”Hisun Chemical), founded in 1998, is a state-holding enterprise invested by State Development & Investment Corporation(SDIC), Zhejiang Hisun Group and ZMC Co., Ltd. The company now covers an area of 312,000 square meters and 35% of its staff members are technicians. With its total assets of nearly USD 60 million, Hisun Chemical has created a niche in agrochemical field through its sustainable researching, marketing efforts and strong distribution network. The company, with its headquarter located in Taizhou, Zhejiang, now has two wholly-owned subsidiary companies , two Sino-foreign joint ventures and one Provincial Hi-tech R&D Centre. Since it was established, Hisun Chemical has already passed ISO9000 & ISO14000 and gained lots of honors like “First AA-level Credit Enterprise of China Pesticide Industry” and “National Hi-tech Enterprise”, etc. Its product, Abamectin has also gained such awards as ”First Prize of S&T Advance Award of China Chemical Industry”, “Major Achievements in National Technologies R&D Program of the 8th Five-year plan of China” and “ Outstanding Project Award in National Technology Innovation Program of the 8th Five-year of China”. Meanwhile, Hisun Chemical has also undertaken the project of Emamectin Benzoate in National Key Technologies R&D program of the 9th Five-year plan of China. And Ascomycin, a kind of its biofungicides, has been listed in “National S&T Pillar Program of Technical Material Development in the 11th Five-year plan of China.” Based on full implement of EHS system and high quality product, Hisun Chemical has been one of the suppliers to many multinational companies, like Bayer, Syngenta, Boehringer Ingelheim and Cheminova, establishing long term business relationship with them. Hisun Chemical exports 85% of its products, ranging from Insecticides, Herbicides to Fungicides, directly to more than 50 countries over the world. Among those products, its patented products such as Oxine copper 33.5% SC & Flazasulfuron have obtained exclusive registration in China. Hisun Chemical adheres to “For Shareholders, For Staff, For Community” as its management purpose, “Honesty, Innovation, Collaboration& Diligence” as its core values, and “Broad Mind& Integrity” as its spirit. With advanced technology, and R&D, Hisun Chemical will strive to become a representative of Agrochemical, Pharmaceutical &Animal Health Field in the 21st century. Our Group-ZHEJIANG HISUN GROUP The original name of Hisun is HaiMen Pharmaceutical Company founded in 1956 and changed her name at 1997 to Zhejiang Hisun Group. Hisun is located in Taizhou, which is a scenic and coastal city at East Sea in China and is part of the southern tip of Shanghai Economic Zone. It contains 100 hectare area and there are more than 3000 employees. Hisun is ranked in the top 520 key enterprises in China, total asset of Hisun has reached RMB 1.6 billion, there is a national R&D center in Hisun and more than 30% of its staff are technician. Hisun has developed into the largest antibiotic and antineoplastic manufacturer and become a reputed one of main chemical production bases in China. There are three main subsidiary companies under Hisun Group which are Hisun pharmaceutical has been listed in SSE, Hisun Chemical and Hisun thermoelectricity. T products of Hisun have been approved and certified by FDA of U.S.A. meanwhile Hisun have got the approvals of ISO9001, ISO9002 and ISO14000. Hisun exports 80% of its products to approximately 100 countries all over the world, the products performance has been approved by domestic and international consumers.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Zhejiang Hisun Chemical Co., Ltd.China Flag
    Country
    Country
    China
    Address
    Address
    No.97 Waisha Road, Jiaojiang District, Taizhou, Zhejiang 318000
    Telephone
    Telephone
    +86 576 88827793
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.hisunchem.com/eabout.asp
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI India

    Not Confirmed

    envelop Contact Supplier

    CPhI India

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Over 500 million syringes of our hyaluronic acid have been safely used worldwide”

    mic“Over 500 million syringes of our hyaluronic acid have been safely used worldwide”

    This week, SpeakPharma interviews Marie-Armelle Floc’h, Chief of Quality and Regulatory Affairs at HTL Biotechnology, a global leader in the development and the manufacturing of pharmaceutical-grade biopolymers headquartered in Javené, Brittany (France). Since 1992, HTL has pioneered the production of hyaluronic acid (HA) through proprietary biofermentation, achieving unmatched purity and consistency for applications in ophthalmology, dermatology and rheumatology. Floc’h highlights how HTL Biotechnology’s compelling portfolio of pharmaceutical-grade biopolymers is built on uncompromising quality standards. These standards have enabled the company to supply biopolymers for over 30 years without a single batch recall, firmly establishing its reputation for reliability and excellence. She also discusses the inauguration of HTL Biotechnology’s new sterile hyaluronic acid production unit — a major milestone that reinforces the company’s leadership in biopolymer manufacturing and enables the development of innovative formulations combining hyaluronic acid with thermo-sensitive active ingredients. This new capability opens the door to advanced biomedical applications where safety, stability and efficacy must be preserved without compromising the integrity of delicate molecules and which requires the highest quality standards. What distinguishes HTL Biotechnology’s biopolymer platforms in the market today? HTL Biotechnology has built its reputation on delivering pharmaceutical‑grade biopolymers (hyaluronic acid, polynucleotides and recombinant collagen) with unmatched purity and consistency. Since its founding in 1992, the company has focused on premium quality positioning. With more than 30 years of experience, HTL Biotechnology guarantees pharmaceutical-grade biopolymers of exceptional purity and exemplary consistency to our clients. We have had no batch recalls in 30 years, a record that underlines the rigor and reliability embedded in our processes. This was made possible by our fully-integrated site in France, where R&D laboratories, GMP manufacturing, quality control, and regulatory expertise are brought together under one roof. Such integration allows us to support our clients seamlessly throughout their product development journey, from early innovation through to global commercialization.Also, the inauguration of our new sterile hyaluronic acid production unit expands the possibilities for our HA to be used in advanced formulations with thermo-sensitive active ingredients, while upholding the uncompromising quality that defines HTL Biotechnology.Our operations are guided by internationally recognized standards, including ISO 13485 certification, which ensures the quality and safety required by medical device manufacturers worldwide.In addition, our Halal certification provides our customers with a significant advantage in accessing and expanding into markets where these requirements are essential for commercialization.Beyond certifications, our commitment to supporting global growth is reflected in the Drug Master Files we maintain across five continents, enabling our clients to accelerate product registration and bring innovative therapies to markets across the world more efficiently. By combining craftsmanship with pharmaceutical rigor, supported by state-of-the-art equipment and advanced bio-production methods, we ensure that every batch produced not only meets the strictest standards, but also delivers the reliability and consistency needed across the entire healthcare ecosystem. HIGHLIGHTS// Biopolymers with unmatched purity/record of no batch recalls/integrated facility in France/operations guided by global standards/new sterile HA unit for advanced formulations  Navigating the complex and evolving regulatory frameworks across global markets can be challenging for healthcare companies. Can you tell us more about how HTL Biotechnology supports its partners in this area? Regulatory support is part of our core premium services offer. We provide pharmaceutical regulatory support to ensure products meet the necessary compliance standards, so our partners can focus on their growth. Our dedicated regulatory professionals bring global and regional expertise, with a team specifically supporting customers in Asia. We offer personalized assistance adapted to their products and to the compliance standards of the target market. This includes personalized case-management support for regulatory file submissions with the concerned health authorities to minimize risks of refusal or delay, with the aim of achieving approval quickly and smoothly.Our offer for regulatory support continues beyond approval. We continuously monitor updates to regulations and provide post-commercialization support to our partners to help them manage any necessary regulatory updates.HIGHLIGHTS// Regulatory support offered as premium service/global and regional expertise/personalized case management for faster approvals/continuous regulatory support  How does HTL Biotechnology integrate sustainability and corporate responsibility into its operations? Sustainability is embedded in HTL Biotechnology’s strategic vision and day-to-day operations. In 2024, the company renewed its commitment to environmental responsibility by reinforcing its corporate social responsibility (CSR) roadmap. Tangible progress was made across multiple fronts: a 27 percent reduction in greenhouse gas emissions per kilogram of HA produced between 2021 and 2024, and a 34 percent reduction in water consumption per kilogram of HA since 2020. In 2024, we renewed the ISO 14001:2015 certification for its environmental management system, reflecting rigorous audit protocols and continual improvement cycles. All employees have been trained in the ISO 14001-certified environmental management system, and 78 percent of critical suppliers have signed HTL Biotechnology’s Responsible Purchasing Charter.These results reflect HTL Biotechnology’s structured and proactive approach to reducing its environmental footprint while maintaining the highest standards of quality and compliance.HIGHLIGHTS// Sustainability embedded in strategic vision/strong CSR roadmap with measurable progress/reduction in greenhouse gas emissions/responsible sourcing 

    Impressions: 923

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/over-500-million-syringes-of-our-hyaluronic-acid-have-been-safely-used-worldwide

    PharmaCompass
    04 Nov 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    ReelPharmaYour API, Our ExpertiseYour API, Our Expertise

    Your API, Our Expertise
    Your API, Our Expertise

    reelYour API, Our Expertise

    This PharmaReel showcases Minakem as a trusted partner for APIs, HPAPIs and steroids from FDA/GMP-certified sites, offering generic & custom solutions and CDMO services from lab to commercial supply, backed by regulatory know-how.

    Impressions: 13

    read-more

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions

    DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions

    The third quarter (Q3) of 2025 witnessed a steady rise in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA). DMFs are used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug productsA total of 323 Type II DMFs were submitted during this period, as opposed to 309 submissions in Q3 2024, marking an increase of 4.53 percent. This is the second highest number since 2018. In Q1 2025, 339 Type II filings were recorded.Across all DMF types (II, III, IV, and V), 479 DMFs were filed in Q3 2025, compared to 394 in Q3 2024, representing a 21.57 percent increase. Out of the 323 Type II DMFs submitted in Q3 2025, 40 had completed their review by the end of Q3, reflecting a processing lag between submission and review completion. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available)China maintains its lead while India posts double-digit growth in DMF submissions China and India continued to dominate DMF submissions in Q3 2025. China retained the top spot with 153 Type II DMFs, matching its submission count from Q3 2024. India recorded 131 DMFs, marking a 20.18 percent increase over 109 filings during the corresponding period last year.The United States stood a distant third with 17 filings, compared to 13 in Q3 2024. Among European nations, Italy recorded eight DMFs, doubling its 2024 tally. The Netherlands filed four, up from three. Spain submitted only one DMF, as against seven submitted in Q3 2024. Taiwan made three filings, up from one submitted in Q3 2024. Together, India, China and Taiwan accounted for about 88.9 percent of all Type II DMFs filed during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) China’s Suzhou Ryway Biotech tops corporate tally; India’s Hetero, Biophore followChina’s Suzhou Ryway Biotech led the company-wise tally with 12 DMF submissions in Q3 2025. The company had not filed any DMFs in Q3 2024.India’s Hetero Group followed with nine DMFs, maintaining the same number of filings as Q3 2024. Biophore India Pharmaceuticals ranked third with six DMFs, doubling its count from three last year.Other notable contributors include Sai Sreyas Pharmaceuticals (India) and Shanghai Haoyuan Chemexpress (China), with five DMFs each. Companies such as SNJ Group, Lunan Pharmaceutical, Allsino Pharmaceutical, Shankus Pharma, Jiangxi Xinganjiang Pharmaceutical, Sunpure Extracts, Lee Pharma, Umedica Laboratories, Linhai Tianyu Pharmaceutical and Maithri Drugs filed four DMFs each. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) Olaparib, semaglutide lead molecular filings; Dr. Reddy’s files DMF for edoxaban & tucatinibDr. Reddy’s Laboratories also featured among key DMF filers in Q3 2025, submitting two DMFs — for edoxaban tosylate monohydrate and tucatinib copovidone. Edoxaban tosylate monohydrate (marketed as Savaysa by Daiichi Sankyo) is a prescription anticoagulant used to reduce the risk of stroke and to treat deep vein thrombosis and pulmonary embolism. Patent exclusivity for Savaysa extends until October 2026 in the United States, with no generic currently available.In terms of molecules, the highest number of DMFs were filed for olaparib, semaglutide, ruxolitinib phosphate, ferric carboxymaltose, and vismodegib, with three DMFs each in Q3 2025.Olaparib, sold by AstraZeneca under the brand name Lynparza, saw DMFs being filed by BDR Lifesciences and Intas Pharmaceuticals from India, and by ScinoPharm Taiwan during the quarter.Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk, continued to draw strong interest from API manufacturers. DMFs for semaglutide were filed by three Chinese companies: Yangzhou Aurisco Pharmaceutical, Zhejiang Peptites Biotech, and Fujian Genohope Biotech.Ruxolitinib phosphate, marketed by Incyte as Jakafi, saw three DMFs. Three Indian companies — Alembic Pharmaceuticals, Valary Labs, and Devi Pharmatech — filed DMFs for this API in Q3 2025. Other molecules that received multiple DMF submissions include ferric carboxymaltose (used to treat iron-deficiency anemia) and vismodegib (an oral therapy for basal-cell carcinoma). View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) First-time DMF filings span 17 companies; India leads with nine first-time DMFs The quarter saw first-time DMF filings from 17 companies. India took a lead here with nine first-time DMF filings, followed by China (six), and the US (two).The DMF filings in this quarter included inclisiran sodium (filed by Aurisco Pharmaceutical of China), pacritinib citrate (by TAPI Nl B.V. of the Netherlands), and vosoritide (by Apicore LLC of the US).Out of the 19 first-time DMFs filed in Q3 2025, four completed their Generic Drug User Fee Amendments (GDUFA) review process during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) GDUFA fee for FY 2026: The FDA Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry.Fee rates for fiscal year 2026 were published on July 30, 2025. FDA has revised fees under GDUFA III across all categories. While there is a slight increase in the DMF fee from US$ 95,084 in 2025 to US$ 102,584 in 2026, the ANDA fee has seen a sharp rise: from US$ 321,920 in 2025 to US$ 358,247 in 2026.FY 2025 and FY 2026 User Fee Rates Generic drug fee category Fees rates for FY 2025 Fees rates for FY 2026 Applications:     Abbreviated New Drug Application (ANDA) US$ 3,21,920 US$ 3,58,247 Drug Master File (DMF) US$ 95,084 US$ 1,02,584 Facilities:     Active Pharmaceutical Ingredient (API)—Domestic US$ 41,580 US$ 43,549 API—Foreign US$ 56,580 US$ 58,549 Finished Dosage Form (FDF)—Domestic US$ 2,31,952 US$ 2,38,943 FDF—Foreign US$ 2,46,952 US$ 2,53,943 Contract Manufacturing Organization (CMO)—Domestic US$ 55,668 US$ 57,346 CMO—Foreign US$ 70,668 US$ 72,346 GDUFA Program:     Large size operation generic drug applicant US$ 18,91,664 US$ 19,18,377 Medium size operation generic drug applicant US$ 7,56,666 US$ 7,67,351 Small business generic drug applicant US$ 1,89,166 US$ 1,91,838 Our viewFor several years prior to the pandemic, India had a lead in Type II DMF submissions. In recent years, China has surpassed India in DMF filings. But Q3 2025 numbers indicate that Indian drugmakers are fast catching up. Since DMFs establish trust in APIs from across the world, we feel this healthy competition between drugmakers from the two countries is good for the global pharmaceutical industry. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 675

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-rise-4-5-in-q3-2025-china-holds-lead-india-records-20-growth-in-submissions

    #PharmaFlow by PHARMACOMPASS
    13 Nov 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    China's Zhejiang Hisun picks up new U.S. deal despite FDA troubles
    China's Zhejiang Hisun picks up new U.S. deal despite FDA troubles

    11 Aug 2016

    // Eric Palmer FIERCE PHARMA

    http://www.fiercepharma.com/manufacturing/china-s-troubled-zhejiang-hisun-keeps-picks-up-new-u-s-business

    Eric Palmer FIERCE PHARMA
    11 Aug 2016
    Share Share

    ABOUT THIS PAGE

    Contact Zhejiang Hisun Chemical Co., Ltd. and get a quotation

    Zhejiang Hisun Chemical Co., Ltd. is a supplier offers 74 products (APIs, Excipients or Intermediates).

    Find a price of 31139-87-4 bulk with JDMF offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of 4-Biphenylacetic Acid bulk with JDMF offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Biotin bulk with JDMF offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Bisbentiamine bulk with JDMF offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Candesartan Cilexetil bulk with JDMF offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Escitalopram Oxalate bulk with JDMF offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Polaprezinc bulk with JDMF offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Procainamide Hydrochloride bulk with JDMF offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Acarbose bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Ademetionine 1,4-Butanedisulfonate bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Ademetionine Disulfate Tosylate bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Adenosine bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Anastrozole bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Apixaban bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Apremilast bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Aripiprazole bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Bedaquiline bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Bicalutamide bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Bleomycin Sulphate bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Cladribine bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Cyclophosphamide bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Cytarabine bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Dactinomycin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Daptomycin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Daunorubicin HCl bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Donepezil bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Doxorubicin Hydrochloride bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Eltrombopag bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Emodepside bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Epirubicin Hydrochloride bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Eprinomectin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Everolimus bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Fipronil bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Fludarabine Phosphate bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Fluralaner bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Fluvastatin Sodium bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Glucosamine Sulfate Sodium Chloride bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Glutathione bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Idarubicin Hydrochloride bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Imidacloprid bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Imipenem + Cilastatin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Immunomycin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Isepamicin Sulfate bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Ivermectin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Letrozole bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Linezolid bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Lovastatin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Lurasidone Hydrochloride bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Meropenem bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Mesna bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Methoprene bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Micafungin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Milbemycin Oxime bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Minocycline Hydrochloride bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Mitomycin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Moxidectin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Mycophenolate Mofetil bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Mycophenolic Acid bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Orlistat bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Oseltamivir Phosphate bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Pirarubicin HCl bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Pravastatin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Praziquantel bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Pyrroloquinoline Quinone Disodium bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Rifamycin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Selamectin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Simvastatin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Sirolimus bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Tacrolimus bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Tazobactam Sodium bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Teicoplanin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Ticagrelor bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Tigecycline bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Find a price of Tulathromycin bulk offered by Zhejiang Hisun Chemical Co., Ltd.

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search